Risperidone drug monitoring. A useful clinical tool?

Clinical Drug Investigation

Volumn 19, Issue 4, 2000, Pages 283-292

  Odou, Pascal ^a,b   Levron, J C ^c   Luyckx, M ^b   Brunet, C ^b   Robert, Hugues ^a,b  

^a EPSM Lille Metropole   (France)

^b UNIV LILLE   (France)

^c Janssen Research Foundation   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CARBAMAZEPINE; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE 4 HYDROXYLASE; NEUROLEPTIC AGENT; PALIPERIDONE; RISPERIDONE; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; FEMALE; FRANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MENTAL DEFICIENCY; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT FAILURE;

EID: 0034051722     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200019040-00006     Document Type: Article

References (35)

1. 1. Leysen JE, Janssen PMF, Schotte A, et al. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology 1993; 112: S40-S54
2. 2. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993; 38 Suppl. 3: S80-8
3. 3. Borison RL. Risperidone: pharmacokinetics. J Clin Psychiatry Monogr 1994; 14 (3): 253-5
4. 4. Heykants J, Huang M-L, Mannens G, et al. The pharmacokinetics of risperidone in humans: a summary. Clin Psychiatry 1994; 55 Suppl. 5: 13-7
5. 5. Mannens G, Huang ML, Meudermans W, et al. Absorption, metabolism and excretion of risperidone in humans. Drug Metab Dispos 1993; 21 (6): 1134-40
6. 6. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57 Suppl. 11: 12-25
7. 7. Van Peer A, Meuldermans W, Woestenborghs R, et al. Clinical pharmacokinetics of rispendone. In: Kane JM, Möller HJ, Awouters F, editors. Serotonin in antipsycholic treatment: mechanisms and clinical practice. New York; Marcel Dekker, 1996: 277-91
8. 8. Barges-Bertocchio MH, Pupeschi G, Levron JC, et al. Carbamazepine (CBZ) induces the metabolism of risperidone, a novel antipsychotic. Proceedings of the Fifth European ISSX Meeting; 1993 Sep 26-29: Vol. 3, no. 186: 186
9. 9. Lane HY, Chang WH. Risperidone-carbamazepine interactions: is cytochrome P450 3A involved? J Clin Psychiatry 1998; 59 (8): 430-1
10. 10. De Leon J, Bork J. Risperidone and cytochrome P450 3A. J Clin Psychiatry 1997; 58: 450
11. 11. Chong SA, Tan CH, Lee EL, et al. Augmentation of risperidone with valproic acid. J Clin Psychiatry 1998; 59 (8): 430-1
12. 12. Guy W. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338, Rockville, (MD): US Department of Health, Education and Welfare, 1976: 217-22
13. 13. Woestenborghs R, Lorreyne W, Van Rompaey F, et al. Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography. J Chromatogr 1992 December; 583 (2): 223-30
14. 14. Odou P, Vaiva G, Luyckx M, et al. Neuroleptics monitoring relation between antipsychotic efficiency and radioreceptor assay concentrations. Eur J Clin Pharmacol 1996; 50: 357-63
15. 15. Bertchy G, Vandel S, Jounel JM, et al. Interaction valpromide-amytriptilline: augmentation de l'amitrytilline et de la nortriptylline par le valpromide. Encéphale 1990; 16: 43-5
16. 16. Nemeroff CB, De Vane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996 March; 153 (3): 311-20
17. 17. Ring BJ, Binkley SN, Vandenbranden M, et al. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 1996 March; 41 (3): 181-6
18. 18. Yeates RA, Scharpf F. Laufen H, et al. Screening for cytochrome P450 3A in man: studies with midazolam and nefidipine. J Pharm Pharmacol 1996 Sept; 48 (9): 933-4
19. 19. Koley AP, Robinson RC, Markowitz A, et al. Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4. Biochem Pharmacol 1997 Feb 21; 53 (4): 455-60
20. 20. Fischer V, Vogels B, Maurer G, et al. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 1992 Mar; 260 (3): 1355-60
21. 21. Linnet K., Olesen OV. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos 1997 Dec; 25 (12): 1379-82
22. 22. Aravagiri M, Marder SR, Wirshing D, et al. Plasma concentrations of risperidone and its 9 hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry 1998; 31: 102-9
23. 23. Darby JK, Pasta DJ, Elfand L, et al. Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the non responder patient in the clinical practice setting. J Clin Psychopharmacol 1997; 17 (6): 478-84
24. 24. Bondolfi G, Baumann P, Dufours H. Treatment resistant schizophreny: clinical experience with new antipsychotics. Eur Neuropharmacol 1996; 6 (2): 521-5
25. 25. Perry PJ, Miller DD, Arndt SV, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148: 231-5
26. 26. Pikar D, Owen RR, Litman RE, et al. Clinical and biologic response to clozapine in patients with schizophrenia. Arch Gen Psychiatry 1992; 49: 345-53
27. 27. Odou P, Frimat B, Fontaine B, et al. Determination of clozapine in serum by receptor assay versus high performance liquid chromatography: possible detection of hydroxy-metabolites. J Clin Pharm Ther 1996; 21: 337-42
28. 28. Davis JM, Ericksen SE, Hurt S, et al. Haloperidol plasma levels and clinical response: basic concepts and clinical data. Psychopharmacol Bull 1985; 21: 48-51
29. 29. Mavroïdis ML, Kanter DR, Hirschowitz J. Plasma haloperidol levels and clinical response: confounding variables. Psychopharmacol Bull 1985; 21: 61-5
30. 30. Smith RC, Vroulis G, Shvartsburg A, et al. RBC and plasma haloperidol and clinical response in schizophrenia. Am J Psychiatry 1982; 139: 1054-6
31. 31. Van Putten T, Marder SR, Mintz J, et al. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 1992: 500-5
32. 32. Miller DD, Hershey LA, Duffy JP. Serum haloperidol concentrations and clinical response in acute psychosis. Drug Intell Clin Pharm 1983; 17: 445
33. 33. Dalh SG. Plasma level monitoring of antipsychotic drugs. Clinical utility. Clin Pharmacokinet 1986; 11: 36-61
34. 34. Balant-Giorgia AE, Gex-Fabry M, Genet C, et al. Therapeutic-drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther Drug Monit 1999; 21: 105-15
35. 35. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9 hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 1999 Feb; 359 (2): 147-51